ArticleBioactive materials2026
From plant to prosthesis: An engineered biomimetic disc repairs senescence-associated intervertebral disc degeneration in goats.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intervertebral disc degeneration (IVDD) is a multifactorial process driven by oxidative stress, inflammation, and cellular senescence, ultimately leading to disc destruction and functional loss. Current treatments can only alleviate symptoms such as low back pain to a certain extent, without addressing the underlying imbalance in the disc microenvironment. In this study, we successfully developed an engineered biomimetic disc, IHP@Yam, which synergistically combines the mesoporous Prussian Blue (HMPB) as a nanozyme and isoliquiritigenin (ISL) for reactive oxygen species (ROS) scavenging, anti-inflammatory, and anti-aging effects, and uses a high-adhesion, highly elastic nature-based yam-derived hydrogel as a disc, aimed at remodeling the degenerative intervertebral disc microenvironment. In vitro experiments demonstrated that isoliquiritigenin-loaded hollow mesoporous prussian blue (IHP) significantly reduced the expression of inflammatory cytokines (TNF-α, IL-1β), matrix-degrading enzymes (MMP9, MMP13), and senescence markers (P16, P21), while promoting the expression of anabolic matrix proteins (ACAN, COL-II), and reducing apoptosis and the number of SA-β-gal-positive cells. Transcriptomic sequencing indicated that IHP treatment markedly inhibited the NF-κB signaling pathway while promoting activation of the AMPK pathway. This was further validated by the downregulation of genes associated with pro-inflammatory signaling, supporting the protective effects observed following IHP intervention. In vivo studies using rat and goat IVDD models showed significant retention of nucleus pulposus hydration, while histological staining confirmed abundant deposition of ACAN and COL-II. In the high-intensity mechanical stress environment of large animal models, IHP@Yam effectively preserved the disc height index (DHI) and inhibited the expression of matrix-degrading enzymes. This study confirms the excellent performance of the IHP@Yam biomimetic disc in improving the degenerative disc microenvironment, providing a reliable therapeutic strategy for intervertebral disc degeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.